ACE inhibitor/ARB use not tied to COVID-19 test positivity

ACE inhibitor/ARB use not tied to COVID-19 test positivity

(HealthDay)—Angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) use is not associated with COVID-19 test positivity, according to a study published online May 5 in JAMA Cardiology.

Neil Mehta, M.B.B.S., from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and colleagues examined the association between use of ACEIs/ARBs and the likelihood of testing positive for COVID-19 in a retrospective cohort study with overlap propensity score weighting. Data were included for 18,472 patients tested for COVID-19, of whom 12.4 percent were taking either ACEIs or ARBs.

The researchers observed a positive COVID-19 test result in 9.4 percent of the patients. Of those who tested positive, 24.3, 9.3, and 6.4 percent were admitted to the hospital, admitted to an , and required mechanical ventilation, respectively. There was no significant association for ACEI and/or ARB use with COVID-19 test positivity in overlap propensity score weighting (odds ratio, 0.97; 95 percent confidence interval, 0.81 to 1.15).

"As there may be a risk to withdrawing these agents, our study, showing no significant greater susceptibility with regard to test positivity, supports the recommendations of several professional societies that have recommended continuation of these medications," the authors write.

One author disclosed financial ties to the pharmaceutical industry.


Explore further

ACEIs/ARBs not linked to severity or mortality of COVID-19

More information: Abstract/Full Text
Editorial
Journal information: JAMA Cardiology

Copyright © 2020 HealthDay. All rights reserved.

Citation: ACE inhibitor/ARB use not tied to COVID-19 test positivity (2020, May 8) retrieved 11 July 2020 from https://medicalxpress.com/news/2020-05-ace-inhibitorarb-tied-covid-positivity.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments